We have the ability to give subcutaneous hydration therapy after preparing the subcutaneous space using hylenex. Does anyone have information on medications that can be given via this route? If you have policies to share I would appreciate it.

Does any organization include monoclonal antibodies (regardless if they are being used for oncologic indications) on their High Alert policy?

We are working on providing data as far as how we are doing in common medication safety metrics, but for many items I am struggling with finding benchmark goals, which are being requested from upper management. For example, we use ISMP's guidance for Alaris Guardrail use and aim for a target goal of 95%, for BCMA we use Leapfrog which has 95% for patient and med identified.

I am curious what others are doing for goals for the below metrics.... Am also curious the size and scope of your organization in order to compare.

We are working on providing data as far as how we are doing in common medication safety metrics, but for many items I am struggling with finding benchmark goals, which are being requested from upper management. For example, we use ISMP's guidance for Alaris Guardrail use and aim for a target goal of 95%, for BCMA we use Leapfrog which has 95% for patient and med identified.

I am curious what others are doing for goals for the below metrics.... Am also curious the size and scope of your organization in order to compare.

Hi everyone,

We are working on removing promethazine injectable from our formulary. I am curious if your institution has done any of the following:
A. Removed promethazine injectable from formulary entirely and do not use non-formulary
B. Allowed injectable promethazine to be used for IV if diluted in pharmacy only
C. Allowed promethazine injectable to be used for IM but not for IV use
D. Removed promethazine from formulary but still allow for use under specific criteria (i.e. cyclic vomiting or refractory to other antiemetics)

Wanting to know if any organizations have transitioned all their controlled substance infusions to the Alaris PCA Syringe Module for the purposes of securing controlled substances.
Interesting in knowing the formulary of medications that you have moved to that platform, any barriers to the change and other lessons learned that you would be able to share.
Thanks!
Lee

Lee M King
Medication Safety Officer
Sparrow Health System
517-364-5564
lee.king@sparrow.org

Does anyone have guidelines on concentration of potassium PHOSPHATE IV infusions to be given peripherally?

At my institution, for potassium CHLORIDE, we use a concentration of 10 mEq/100 mL (0.1 mEq/mL) for peripheral administration and up to 20 mEq/100 mL (0.2 mEq/mL) for central lines.

Our EHR (Epic) is set up to default all potassium PHOSPHATE doses to be diluted in 250 mL NS to infuse over 6 hours.

My hospital recently converted infusion pumps to the B Braun Infusomat Large Volume Pump. We are having some workflow issues in our critical care units. I would like to connect with anyone who currently uses these pumps in a critical care area to ask a few workflow questions. Please email me at kristen.r.rachinski@kp.org
Thank you!
Kristen

Colleagues:

As a courtesy to Eli Lilly and Company, as directed by the FDA, ISMP is emailing you to notify you of a bamlanivimab Dear HCP letter containing the following message:

"Refer only to the FDA Authorized Fact Sheet for bamlanivimab for preparation and administration instructions and disregard a document entitled “Bamlanivimab Alternative Preparation and Administration Information.”

Please see the attached letter to review the Dear HCP letter.

Mike

Hello All,
We are currently building the batched product formulary for our IV workflow software (BD IV Prep) at the system level. At this point, our health system consists of one academic medical center with several community hospitals.